Carimune IGIV and Ropinirole Hydrochloride

• Generic Name: immune globulin intravenous
• Dosage Forms: injection, powder, lyophilized, for solution
• Other Brand Names: Carimune, Flebogamma, Gammaplex, Octagam, Privigen, Bivigam, Carimene N/F, Flebogamma DIF, Octagam Gammagard S/D, Gammagard S/D, Sandoglobulin, Venoglobulin-S 5%, Venoglobulin-S 10%, Gammar IV, Gammar-P IV, Iveegam, Polygam S/D, Gamimune N 5%, Gamimune N 10%, Panglobulin, Iveegam EN, Gamunex, Panglobulin NF, Gammagard, Panzyga

Immune globulin intravenous (IGIV) is a sterilized solution made from human plasma. It contains the antibodies to help your body protect itself against infection from various diseases.

IGIV is used to treat primary immunodeficiency (PI), and to reduce the risk of infection in individuals with poorly functioning immune systems such as those with chronic lymphocytic leukemia (CLL). IGIV is also used to increase platelets (blood clotting cells) in people with idiopathic thrombocytopenic purpura (ITP) and to prevent aneurysm caused by a weakening of the main artery in the heart associated with Kawasaki syndrome.

IGIV is also used to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a debilitating nerve disorder that causes muscle weakness and can affect daily activities.

IGIV may also be used for purposes not listed in this medication guide.

• Generic Name: ropinirole
• Dosage Forms: n.a.
• Other Brand Names: Requip, Requip XL, ReQuip Follow on Pack, ReQuip Starter Pack, Repreve, Requip Starter Kit

Symptomatic management of idiopathic parkinsonian syndrome.

Used as an adjunct to levodopa for the symptomatic management of parkinsonian syndrome in patients with advanced disease.

Also used as monotherapy for the initial symptomatic management of parkinsonian syndrome. Most clinicians would use levodopa for initial therapy in individuals >70 years of age (less likely than younger individuals to develop levodopa-related motor complications and because of concerns about cognitive dysfunction), in patients with cognitive impairment, and in those with severe disease. A dopamine receptor agonist may be preferred for initial therapy in patients ≤70 years of age.

Symptomatic management of moderate-to-severe primary restless legs syndrome (Ekbom syndrome).